acute myeloid leukemia
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnosed with AML(not APL);To be aged 18~65 years; Liver and renal function: serum bilirubin<=35umol/L, AST/ALT lower than 2* upper normal serum level, creatinine<=150umol/L; Normal cardiac function: NYHA I/II; Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2; Non-pregnant and non-nursing; Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test to rule out pregnancy; Women of child-bearing potential must either commit to take birth control measures at least four weeks before she begins dasatinib therapy; Men must agree not to father a child and must use a latex condom during any sexual contact with women of childbearing potential while taking dasatinib and for 3 months after therapy is stopped; Signed written informed consent.
Exclusion criteria
Exclusion criteria: APL; Liver and renal insufficiency (beyond the inclusion criteria); Patients with ejection fraction 2); Patients with a "currently active" second malignancy; Patients with "currently active" tuberculosis. Patients with HIV;active HBV, HCV, or Hepatitis A infection; Patients who can't understand or obey the protocol; atients participated in other clinical trial; Other circumstance that obstructs the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event Free Survival;Overall survival;recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Death Rate;Toxicity and Safety; | — |
Countries
China
Contacts
Public ContactShifeng Lou
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed